Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione

AIM: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9) and of a key pharmacologic target of vitamin K antagonists, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to coumarin derivatives. The role of these variants in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lacut, Karine, Ayme-Dietrich, Estelle, Gourhant, Lenaick, Poulhazan, Elise, Andro, Marion, Becquemont, Laurent, Mottier, Dominique, Le Gal, Gregoire, Verstuyft, Celine
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2012
Assuntos:
Pharmacogenetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3370347/
https://ncbi.nlm.nih.gov/pubmed/21883387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.04095.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados